HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles Alnylam Pharmaceuticals Receives EC Approval for AMVUTTRA® for the Treatment of ATTR Amyloidosis with Cardiomyopathy June 9, 2025 0 Important News For Vera Therapeutics June 2, 2025 0 Alnylam Pharmaceuticals Reported Its Q1 2025 Financial Results and Highlights Recent Period Progress May 1, 2025 0 BridgeBio Pharma to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy at the ACC Annual Scientific Sessions March 24, 2025 0